Pharmaceutical and biotech companies want to speed up regulatory submissions for a number of strategic reasons. Competitors are close behind. Investors are eager to see progress. And most importantly, new therapies will enhance or even save patient lives.
The most effective cross-functional submissions teams work together, and with their executive leaders, to set and achieve reasonable but accelerated milestones. Here’s how project managers can do their part to speed up investigational new drug applications (IND), new drug applications (NDA), biologic license applications (BLA), and other submissions.
For ways that other regulatory roles can work faster, as well as real-world examples of how they did so, download Working Together to Accelerate Regulatory Submissions.
Monroe Hatch is Senior Director of Corporate Business Development and IPM’s Pharmaceuticals and Biotech industry lead. Monroe has led and consulted on strategy development and execution with many pharmaceutical, biotechnology, medical device, and healthcare companies in areas including product development framework and processes, project and portfolio management, and customer satisfaction.
"*" indicates required fields
Monroe Hatch is Senior Director of Corporate Business Development and IPM’s Pharmaceuticals and Biotech industry lead. Monroe has led and consulted on strategy development and execution with many pharmaceutical, biotechnology, medical device, and healthcare companies in areas including product development framework and processes, project and portfolio management, and customer satisfaction.